Flavio Solca - Concepedia

Author

Flavio Solca

Boehringer Ingelheim (Austria)ORCID

Also Known As

F F Solca, F Solca, F. Solca, FLAVIO SOLCA, Flavio F. Solca, Flavio F.A. Solcà, Flavio Solca, Solca, Flavio

197

Publications

5.3K

Citations

H-Index

Concepts

All Affiliations

Boehringer Ingelheim (Austria)Boehringer Ingelheim (Germany)Dana-Farber Cancer Institute Vall d'Hebron Hospital Universitari Boehringer Ingelheim (Denmark)

About

Flavio Solca is an author at Boehringer Ingelheim (Austria) specializing in medicine, cell biology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	28	2.8K
2	Cell Biology	15	17	2.6K
3	Biochemistry	3	3	322
4	Health Sciences	2	2	29
5	Natural Sciences	1	1	64

Flavio Solca

Publications

4.7K

Citations

H-Index

Page 1

	Year	Citations
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models D Li, Lauren Ambrogio, Takeshi Shimamura, Oncogene Systems BiologyMedicineBronchial NeoplasmIrreversible Egfr/her2 InhibitorCancer Treatment	2008	1.4K
Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker Flavio Solca, G. Dahl, Andreas Zoephel, Journal of Pharmacology and Experimental Therapeutics	2012	848
Characterization of receptors for alpha-melanocyte-stimulating hormone on human melanoma cells. Walter Siegrist, Flavio Solca, Sibylla Stutz, PubMed ImmunologyTumor BiologyPhotoaffinity Cross-linkingClinical ChemistryCell Signaling	1989	222
Activation of IL-6R/JAK1/STAT3 Signaling Induces <i>De Novo</i> Resistance to Irreversible EGFR Inhibitors in Non–Small Cell Lung Cancer with T790M Resistance Mutation Sun Mi Kim, Oh-Joon Kwon, Yun Hong, Molecular Cancer Therapeutics Irreversible Egfr InhibitorsCell SignalingT790m Resistance MutationStronger Stat3 ActivationImmunology	2012	194
HER2 <sup>YVMA</sup> drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy Samanthi A. Perera, Danan Li, Takeshi Shimamura, Proceedings of the National Academy of Sciences ImmunologyPathologyCancer BiologyRapid DevelopmentTumor Biology	2009	178
Hedgehog‐EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumour‐initiating pancreatic cancer cells Markus Eberl, Stefan Klingler, Doris Mangelberger, EMBO Molecular Medicine OncologyDevelopmental BiologyPancreatic CancerMedicineCancer Cell Biology	2012	167
Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors Harald Engelhardt, Dietrich Böse, Mark Petronczki, Journal of Medicinal Chemistry	2019	139
Glycolysis Inhibition Sensitizes Non–Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation Sun Mi Kim, Mi Ran Yun, Yun Hong, Molecular Cancer Therapeutics T790m MutationCancer BiologyTumor BiologyOncologyCancer Cell Biology	2013	92
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer Ezra E.W. Cohen, Lisa Licitra, Barbara Burtness, Annals of Oncology	2017	78
Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells Nikolaos Ioannou, Angus Dalgleish, Alan M. Seddon, British Journal of Cancer	2011	72

Page 1